布仑妥昔单抗维多汀
医学
霍奇金淋巴瘤
肿瘤科
内科学
阶段(地层学)
淋巴瘤
生物
古生物学
作者
Stephen M. Ansell,John Radford,Joseph M. Connors,Monika Długosz‐Danecka,Won-Seog Kim,Andrea Gallamini,Radhakrishnan Ramchandren,Jonathan W. Friedberg,Ranjana H. Advani,Martin Hutchings,Andrew M. Evens,Piotr Smolewski,Kerry J. Savage,Nancy L. Bartlett,Hyeon‐Seok Eom,Jeremy S. Abramson,Cassie Dong,Frank Campana,Keenan Fenton,Markus Puhlmann
标识
DOI:10.1056/nejmoa2206125
摘要
Patients who received A+AVD for the treatment of stage III or IV Hodgkin's lymphoma had a survival advantage over those who received ABVD. (Funded by Takeda Development Center Americas and Seagen; ECHELON-1 ClinicalTrials.gov number, NCT01712490; EudraCT number, 2011-005450-60.).
科研通智能强力驱动
Strongly Powered by AbleSci AI